Trevi Therapeutics (TRVI) PT Raised to $10 at Needham & Company on Haduvio Data, "Valuation Discounts Potential"

June 29, 2022 4:14 PM EDT
Get Alerts TRVI Hot Sheet
Price: $1.75 -9.33%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 58
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Serge Belanger raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $10.00 (from $8.00) while maintaining a Buy rating, on the company's report of Haduvio Phase 2b/3 data.

The analyst comments: "TRVI's Ph 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) as a treatment for prurigo nodularis (PN) successfully met the key primary and secondary endpoints. Haduvio had a quick onset of action reaching stat sig at 6-weeks with efficacy that had yet to plateau at the wk-14 readout. Haduvio's safety/tolerability was consistent with prior trials where incidences of nausea, dizziness, headache led to study discontinuations, the bulk of which occurred in the two-wk titration period. TRVI plans to meet with FDA prior to initiating a second pivotal study. This is the second program de-risking trial readout for Haduvio in 1H22. We continue to believe TRVI's valuation discounts Haduvio's potential in both IPF cough and PN. We maintain our Buy rating, and adjust our $PT to $10 (from $8) to reflect additional de-risking of the PN program."

By Vlad Schepkov

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Needham & Company, FDA, Vlad Schepkov